Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Syndicate
Applied Therapeutics prices $30M offering of common stock and warrants » 06:23
06/23/22
06/23
06:23
06/23/22
06:23
APLT

Applied Therapeutics

$1.07 /

-0.01 (-0.93%)

Applied Therapeutics…

Applied Therapeutics announced the pricing of its underwritten public offering of 20.0M shares of its common stock, par value $0.0001 per share, 10.0M pre-funded warrants to purchase common stock in lieu of common stock to certain investors, and accompanying warrants to purchase up to 30.0M shares of its common stock. Each share of common stock and accompanying common warrant are being offered at a combined public offering price of $1.00, less underwriting discounts and commissions, and each pre-funded warrant and accompanying common warrant are being offered at a combined public offering price of $0.9999, less underwriting discounts and commissions. The pre-funded warrants have an exercise price of $0.0001 per share and the common warrants have an exercise price of $1.00 per share. The pre-funded warrants and the common warrants are immediately exercisable and will expire five years from the date of issuance. The gross proceeds to the Company from the offering, before deducting the underwriting discounts and commissions and offering expenses payable by the Company, are expected to be $30M. SVB Securities is acting as the sole book-running manager for the offering. The offering is expected to close on June 27, 2022.

ShowHide Related Items >><<
APLT Applied Therapeutics
$1.07 /

-0.01 (-0.93%)

APLT Applied Therapeutics
$1.07 /

-0.01 (-0.93%)

04/13/22 Truist
Applied Therapeutics price target lowered to $6 from $85 at Truist
03/21/22 Barclays
Applied Therapeutics price target lowered to $2.50 from $7 at Barclays
01/05/22 Citi
Applied Therapeutics price target lowered to $30 from $38 at Citi
01/04/22 Goldman Sachs
Applied Therapeutics price target lowered to $3 from $10 at Goldman Sachs
APLT Applied Therapeutics
$1.07 /

-0.01 (-0.93%)

  • 23
    Jun
APLT Applied Therapeutics
$1.07 /

-0.01 (-0.93%)

APLT Applied Therapeutics
$1.07 /

-0.01 (-0.93%)

On The Fly
Fly Intel: After-Hours Movers » 17:57
06/22/22
06/22
17:57
06/22/22
17:57
SCS

Steelcase

$10.44 /

+0.02 (+0.19%)

, WOR

Worthington

$40.40 /

-0.56 (-1.37%)

, KBH

KB Home

$26.22 /

+0.62 (+2.42%)

, FUL

H.B. Fuller

$61.45 /

+0.08 (+0.13%)

, APLT

Applied Therapeutics

$1.07 /

-0.01 (-0.93%)

, RMTI

Rockwell Medical

$1.28 /

-0.02 (-1.54%)

, XENE

Xenon Pharmaceuticals

$34.68 /

+1.84 (+5.60%)

Check out this evening's…

ShowHide Related Items >><<
XENE Xenon Pharmaceuticals
$34.68 /

+1.84 (+5.60%)

WOR Worthington
$40.40 /

-0.56 (-1.37%)

SCS Steelcase
$10.44 /

+0.02 (+0.19%)

RMTI Rockwell Medical
$1.28 /

-0.02 (-1.54%)

KBH KB Home
$26.22 /

+0.62 (+2.42%)

FUL H.B. Fuller
$61.45 /

+0.08 (+0.13%)

APLT Applied Therapeutics
$1.07 /

-0.01 (-0.93%)

SCS Steelcase
$10.44 /

+0.02 (+0.19%)

WOR Worthington
$40.40 /

-0.56 (-1.37%)

08/23/21 Seaport Global
Worthington initiated with a Neutral at Seaport Global
KBH KB Home
$26.22 /

+0.62 (+2.42%)

06/16/22 UBS
KB Home price target lowered to $45 from $66 at UBS
06/08/22 Barclays
KB Home price target lowered to $44 from $47 at Barclays
05/13/22 Wolfe Research
KB Home downgraded to Underperform from Peer Perform at Wolfe Research
04/13/22 JPMorgan
KB Home price target lowered to $39 from $49 at JPMorgan
FUL H.B. Fuller
$61.45 /

+0.08 (+0.13%)

04/18/22 Deutsche Bank
H.B. Fuller upgraded on 'significant valuation upside' at Deutsche Bank
04/18/22 Deutsche Bank
H.B. Fuller upgraded to Buy from Hold at Deutsche Bank
04/14/22 Baird
H.B. Fuller upgraded to Outperform at Baird after underperformance
04/14/22 Baird
H.B. Fuller upgraded to Outperform from Neutral at Baird
APLT Applied Therapeutics
$1.07 /

-0.01 (-0.93%)

04/13/22 Truist
Applied Therapeutics price target lowered to $6 from $85 at Truist
03/21/22 Barclays
Applied Therapeutics price target lowered to $2.50 from $7 at Barclays
01/05/22 Citi
Applied Therapeutics price target lowered to $30 from $38 at Citi
01/04/22 Goldman Sachs
Applied Therapeutics price target lowered to $3 from $10 at Goldman Sachs
RMTI Rockwell Medical
$1.28 /

-0.02 (-1.54%)

01/18/22 H.C. Wainwright
Rockwell Medical price target lowered to $3 from $5 at H.C. Wainwright
XENE Xenon Pharmaceuticals
$34.68 /

+1.84 (+5.60%)

11/11/21 SVB Securities
Xenon Pharmaceuticals price target raised to $40 from $34 at SVB Leerink
10/28/21 RBC Capital
Xenon Pharmaceuticals initiated with an Outperform at RBC Capital
10/06/21 Wedbush
Wedbush remains bullish on Xenon as financing gives firepower to advance XEN1101
10/04/21 Jefferies
Jefferies ups Xenon target to $50 after 'home run' epilepsy data
XENE Xenon Pharmaceuticals
$34.68 /

+1.84 (+5.60%)

WOR Worthington
$40.40 /

-0.56 (-1.37%)

SCS Steelcase
$10.44 /

+0.02 (+0.19%)

KBH KB Home
$26.22 /

+0.62 (+2.42%)

FUL H.B. Fuller
$61.45 /

+0.08 (+0.13%)

APLT Applied Therapeutics
$1.07 /

-0.01 (-0.93%)

  • 23
    Jun
  • 06
    Oct
KBH KB Home
$26.22 /

+0.62 (+2.42%)

APLT Applied Therapeutics
$1.07 /

-0.01 (-0.93%)

WOR Worthington
$40.40 /

-0.56 (-1.37%)

SCS Steelcase
$10.44 /

+0.02 (+0.19%)

KBH KB Home
$26.22 /

+0.62 (+2.42%)

FUL H.B. Fuller
$61.45 /

+0.08 (+0.13%)

APLT Applied Therapeutics
$1.07 /

-0.01 (-0.93%)

KBH KB Home
$26.22 /

+0.62 (+2.42%)

FUL H.B. Fuller
$61.45 /

+0.08 (+0.13%)

Syndicate
Applied Therapeutics announces common stock, warrants offering » 16:11
06/22/22
06/22
16:11
06/22/22
16:11
APLT

Applied Therapeutics

$1.07 /

-0.01 (-0.93%)

Applied Therapeutics…

Applied Therapeutics announced that it plans to make a public offering of shares of its common stock, or pre-funded warrants to purchase common stock in lieu of common stock to certain investors, and accompanying warrants to purchase shares of its common stock, in an underwritten registered public offering. The company intends to use the net proceeds from this offering for general corporate purposes. General corporate purposes may include research and development costs, including the conduct of clinical trials and process development and manufacturing of the company's product candidates, expansion of the company's research and development capabilities, working capital and capital expenditures. SVB Securities is acting as the sole book-running manager for the offering.

ShowHide Related Items >><<
APLT Applied Therapeutics
$1.07 /

-0.01 (-0.93%)

APLT Applied Therapeutics
$1.07 /

-0.01 (-0.93%)

04/13/22 Truist
Applied Therapeutics price target lowered to $6 from $85 at Truist
03/21/22 Barclays
Applied Therapeutics price target lowered to $2.50 from $7 at Barclays
01/05/22 Citi
Applied Therapeutics price target lowered to $30 from $38 at Citi
01/04/22 Goldman Sachs
Applied Therapeutics price target lowered to $3 from $10 at Goldman Sachs
APLT Applied Therapeutics
$1.07 /

-0.01 (-0.93%)

APLT Applied Therapeutics
$1.07 /

-0.01 (-0.93%)

APLT Applied Therapeutics
$1.07 /

-0.01 (-0.93%)

Over a month ago
Hot Stocks
Applied receives orphan medicinal product designation from EMA for AT-007 » 07:02
06/03/22
06/03
07:02
06/03/22
07:02
APLT

Applied Therapeutics

$1.21 /

-0.09 (-6.92%)

Applied Therapeutics…

Applied Therapeutics announced designation of AT-007 as an orphan medicinal product by the European Medicines Agency, EMA, for treatment of Galactosemia. "We are pleased that the EMA has recognized the high unmet medical need in Galactosemia, the role of galactitol as the toxic metabolite responsible for long-term complications in Galactosemia, and the potential benefit of AT-007 treatment in reducing toxic galactitol levels," said Shoshana Shendelman, PhD, Founder and CEO of Applied Therapeutics. "Orphan designation for AT-007 marks an important step towards advancing our regulatory initiatives in Europe. We plan to meet with the EMA in the third quarter to discuss a potential MAA submission in Europe for conditional approval based on available biomarker data or for full approval based on expected clinical outcomes data."

ShowHide Related Items >><<
APLT Applied Therapeutics
$1.21 /

-0.09 (-6.92%)

APLT Applied Therapeutics
$1.21 /

-0.09 (-6.92%)

04/13/22 Truist
Applied Therapeutics price target lowered to $6 from $85 at Truist
03/21/22 Barclays
Applied Therapeutics price target lowered to $2.50 from $7 at Barclays
01/05/22 Citi
Applied Therapeutics price target lowered to $30 from $38 at Citi
01/04/22 Goldman Sachs
Applied Therapeutics price target lowered to $3 from $10 at Goldman Sachs
APLT Applied Therapeutics
$1.21 /

-0.09 (-6.92%)

APLT Applied Therapeutics
$1.21 /

-0.09 (-6.92%)

APLT Applied Therapeutics
$1.21 /

-0.09 (-6.92%)

Earnings
Applied Therapeutics reports Q1 EPS (88c), consensus (83c) » 07:01
05/12/22
05/12
07:01
05/12/22
07:01
APLT

Applied Therapeutics

$1.76 /

-0.065 (-3.57%)

Cash and cash equivalents…

Cash and cash equivalents and short-term investments totaled $55.7M as of March 31, 2022, compared with $80.8M at December 31, 2021. "We made significant progress in the first quarter across all three of our Phase 3 programs," said CEO Shoshana Shendelman. "We are pleased to have reached alignment with the FDA on Galactosemia, and are excited about the expected milestones in the year ahead."

ShowHide Related Items >><<
APLT Applied Therapeutics
$1.76 /

-0.065 (-3.57%)

APLT Applied Therapeutics
$1.76 /

-0.065 (-3.57%)

04/13/22 Truist
Applied Therapeutics price target lowered to $6 from $85 at Truist
03/21/22 Barclays
Applied Therapeutics price target lowered to $2.50 from $7 at Barclays
01/05/22 Citi
Applied Therapeutics price target lowered to $30 from $38 at Citi
01/04/22 Goldman Sachs
Applied Therapeutics price target lowered to $3 from $10 at Goldman Sachs
APLT Applied Therapeutics
$1.76 /

-0.065 (-3.57%)

APLT Applied Therapeutics
$1.76 /

-0.065 (-3.57%)

APLT Applied Therapeutics
$1.76 /

-0.065 (-3.57%)

Recommendations
Applied Therapeutics price target lowered to $6 from $85 at Truist » 07:23
04/13/22
04/13
07:23
04/13/22
07:23
APLT

Applied Therapeutics

$2.01 /

-0.19 (-8.64%)

Truist analyst Robyn…

Truist analyst Robyn Karnauskas lowered the firm's price target on Applied Therapeutics to $6 from $85 and keeps a Buy rating on the shares as part of a broader research note on Biotech. The analyst is adjusting her model as AT007 for pediatric galactosemia patients was pushed back to launch in 2024 from 2022 given the need for hard outcomes data and also taking out assumed revenue for adult patient population given that the ongoing pivotal trial is only in pediatric population.

ShowHide Related Items >><<
APLT Applied Therapeutics
$2.01 /

-0.19 (-8.64%)

APLT Applied Therapeutics
$2.01 /

-0.19 (-8.64%)

03/21/22 Barclays
Applied Therapeutics price target lowered to $2.50 from $7 at Barclays
01/05/22 Citi
Applied Therapeutics price target lowered to $30 from $38 at Citi
01/04/22 Goldman Sachs
Applied Therapeutics price target lowered to $3 from $10 at Goldman Sachs
01/04/22 Baird
Applied Therapeutics price target lowered to $21 from $35 at Baird
APLT Applied Therapeutics
$2.01 /

-0.19 (-8.64%)

APLT Applied Therapeutics
$2.01 /

-0.19 (-8.64%)

APLT Applied Therapeutics
$2.01 /

-0.19 (-8.64%)

Over a quarter ago
Recommendations
Applied Therapeutics price target lowered to $2.50 from $7 at Barclays » 05:51
03/21/22
03/21
05:51
03/21/22
05:51
APLT

Applied Therapeutics

$1.88 /

+0.05 (+2.73%)

Barclays analyst Carter…

Barclays analyst Carter Gould lowered the firm's price target on Applied Therapeutics to $2.50 from $7 and keeps an Equal Weight rating on the shares. Applied recently announced Q4 results, notably disclosing a going concern risk given the company's cash position and historical burn rate, Gould tells investors in a research note. The analyst says that even with a lower burn going forward, the company's cash position will remain an overhang until addressed.

ShowHide Related Items >><<
APLT Applied Therapeutics
$1.88 /

+0.05 (+2.73%)

APLT Applied Therapeutics
$1.88 /

+0.05 (+2.73%)

01/05/22 Citi
Applied Therapeutics price target lowered to $30 from $38 at Citi
01/04/22 Goldman Sachs
Applied Therapeutics price target lowered to $3 from $10 at Goldman Sachs
01/04/22 Baird
Applied Therapeutics price target lowered to $21 from $35 at Baird
01/04/22 Barclays
Applied Therapeutics downgraded to Equal Weight from Overweight at Barclays
APLT Applied Therapeutics
$1.88 /

+0.05 (+2.73%)

APLT Applied Therapeutics
$1.88 /

+0.05 (+2.73%)

APLT Applied Therapeutics
$1.88 /

+0.05 (+2.73%)

Earnings
Applied Therapeutics reports FY21 EPS ($4.12), consensus ($4.38) » 07:36
03/10/22
03/10
07:36
03/10/22
07:36
APLT

Applied Therapeutics

$1.75 /

+0.045 (+2.64%)

Cash and cash equivalents…

Cash and cash equivalents and short-term investments totaled $80.8 million as of December 31, 2021, compared with $96.8 million at December 31, 2020. "We remain committed to bringing new treatments to patients in areas of high unmet need," said Shoshana Shendelman, PhD, Founder and CEO of Applied Therapeutics. "With three ongoing Phase 3 studies across Galactosemia, Sorbitol Dehydrogenase Deficiency and Diabetic Cardiomyopathy, we are advancing treatments forward, and expect multiple catalysts and opportunities for value creation in 2022 and 2023."

ShowHide Related Items >><<
APLT Applied Therapeutics
$1.75 /

+0.045 (+2.64%)

APLT Applied Therapeutics
$1.75 /

+0.045 (+2.64%)

01/05/22 Citi
Applied Therapeutics price target lowered to $30 from $38 at Citi
01/04/22 Goldman Sachs
Applied Therapeutics price target lowered to $3 from $10 at Goldman Sachs
01/04/22 Baird
Applied Therapeutics price target lowered to $21 from $35 at Baird
01/04/22 Barclays
Applied Therapeutics downgraded to Equal Weight from Overweight at Barclays
APLT Applied Therapeutics
$1.75 /

+0.045 (+2.64%)

APLT Applied Therapeutics
$1.75 /

+0.045 (+2.64%)

APLT Applied Therapeutics
$1.75 /

+0.045 (+2.64%)

Hot Stocks
Applied Therapeutics supports annual Rare Disease Day » 07:45
02/28/22
02/28
07:45
02/28/22
07:45
APLT

Applied Therapeutics

$1.99 /

+0.04 (+2.05%)

Applied Therapeutics is…

Applied Therapeutics is recognizing the 15th Annual Rare Disease Day to help elevate awareness of rare diseases and call attention to the unique challenges facing people with rare diseases. Applied Therapeutics is proud to support Rare Disease Day events across the U.S., including participating in the 5th Annual GLOW for Galactosemia Event in Knoxville, Tennessee, and virtually supporting GLOW teams across the country as they raise awareness of Galactosemia, a rare genetic metabolic disease resulting in an inability to metabolize the sugar galactose, which is found in foods and is also synthesized by the body. The company is collaborating with advocacy partners on a wide range of Galactosemia initiatives throughout the year, including Race 4 Jase and Fore Joey's Cause. Applied Therapeutics is also partnering with the Charcot-Marie-Tooth Foundation and the Hereditary Neuropathy Foundation to raise awareness of SORD Deficiency, a rare disease which results in a progressive, debilitating hereditary neuropathy.

ShowHide Related Items >><<
APLT Applied Therapeutics
$1.99 /

+0.04 (+2.05%)

APLT Applied Therapeutics
$1.99 /

+0.04 (+2.05%)

01/05/22 Citi
Applied Therapeutics price target lowered to $30 from $38 at Citi
01/04/22 Goldman Sachs
Applied Therapeutics price target lowered to $3 from $10 at Goldman Sachs
01/04/22 Baird
Applied Therapeutics price target lowered to $21 from $35 at Baird
01/04/22 Barclays
Applied Therapeutics downgraded to Equal Weight from Overweight at Barclays
APLT Applied Therapeutics
$1.99 /

+0.04 (+2.05%)

APLT Applied Therapeutics
$1.99 /

+0.04 (+2.05%)

APLT Applied Therapeutics
$1.99 /

+0.04 (+2.05%)

Conference/Events
Applied Therapeutics participates in a conference call with Truist » 09:25
01/07/22
01/07
09:25
01/07/22
09:25
APLT

Applied Therapeutics

$4.25 /

-0.245 (-5.46%)

Healthcare Analyst…

Healthcare Analyst Karnauskas holds a conference call to discuss SORD deficiency with an expert on January 7 at 10 am hosted by Truist.

ShowHide Related Items >><<
APLT Applied Therapeutics
$4.25 /

-0.245 (-5.46%)

APLT Applied Therapeutics
$4.25 /

-0.245 (-5.46%)

01/05/22 Citi
Applied Therapeutics price target lowered to $30 from $38 at Citi
01/04/22 Goldman Sachs
Applied Therapeutics price target lowered to $3 from $10 at Goldman Sachs
01/04/22 Baird
Applied Therapeutics price target lowered to $21 from $35 at Baird
01/04/22 Barclays
Applied Therapeutics downgraded to Equal Weight from Overweight at Barclays
APLT Applied Therapeutics
$4.25 /

-0.245 (-5.46%)

  • 12
    Feb
APLT Applied Therapeutics
$4.25 /

-0.245 (-5.46%)

APLT Applied Therapeutics
$4.25 /

-0.245 (-5.46%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.